C88.01

Clinical Causes: The exact cause of Waldenström macroglobulinemia is unknown, but it involves genetic mutations that lead to abnormal growth of lymphoplasmacytic cells. It may be influenced by genetic factors, although no specific hereditary link has been definitively identified. Environmental exposures, such as pesticides or chemicals, could play a role, but evidence remains inconclusive. Aging is a significant factor, with the condition most commonly diagnosed in middle-aged or older adults.

Key Symptoms: Fatigue and weakness Unusual bruising or bleeding High levels of immunoglobulin M (IgM), leading to blood hyperviscosity Blurred or double vision Headaches or dizziness Numbness or tingling sensations in extremities Weight loss and loss of appetite Swelling of lymph nodes, spleen, or liver Recurrent infections

Diagnosis Path: Diagnosing Waldenström macroglobulinemia involves several steps, including blood tests that measure immunoglobulin levels and the number of abnormal cells. A bone marrow biopsy may be performed to assess marrow involvement. Additionally, imaging studies like CT scans can evaluate the extent of organ involvement. Because the disease can vary greatly between individuals, diagnosis often requires a combination of laboratory and clinical assessments.

Treatment Protocols: Treatment options depend on disease activity and symptoms. When in remission, the focus may be on monitoring and preventing relapse, often called watchful waiting. If treatment is necessary, options might include chemotherapy, targeted therapies, immunotherapy, and plasmapheresis to reduce blood viscosity. Managing symptoms and supporting overall health are essential aspects of care, with regular follow-up to detect any signs of disease progression.